ZA201903093B - Crystalline forms of a magl inhibitor - Google Patents
Crystalline forms of a magl inhibitorInfo
- Publication number
- ZA201903093B ZA201903093B ZA2019/03093A ZA201903093A ZA201903093B ZA 201903093 B ZA201903093 B ZA 201903093B ZA 2019/03093 A ZA2019/03093 A ZA 2019/03093A ZA 201903093 A ZA201903093 A ZA 201903093A ZA 201903093 B ZA201903093 B ZA 201903093B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline forms
- magl inhibitor
- magl
- inhibitor
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423126P | 2016-11-16 | 2016-11-16 | |
| PCT/US2017/061875 WO2018093953A1 (en) | 2016-11-16 | 2017-11-15 | Crystalline forms of a magl inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201903093B true ZA201903093B (en) | 2020-11-25 |
Family
ID=62145805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/03093A ZA201903093B (en) | 2016-11-16 | 2019-05-17 | Crystalline forms of a magl inhibitor |
Country Status (38)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028085B1 (ru) | 2012-01-06 | 2017-10-31 | Эбайд Терапьютикс, Инк. | Карбаматные соединения и их применение |
| WO2016183097A1 (en) | 2015-05-11 | 2016-11-17 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| MX393241B (es) | 2016-11-16 | 2025-03-24 | H Lundbeck As | Formulaciones farmaceuticas. |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| RS65016B1 (sr) | 2016-11-16 | 2024-01-31 | H Lundbeck As | Kristalni oblik magl inhibitora |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| UA124990C2 (uk) | 2017-05-23 | 2021-12-22 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Інгібітори magl на основі піразолу |
| CN111050765B (zh) | 2017-08-29 | 2024-01-02 | H.隆德贝克有限公司 | 螺环化合物及其制造和使用方法 |
| SG11202011228TA (en) * | 2018-05-15 | 2020-12-30 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| BR112021000109A2 (pt) * | 2018-07-19 | 2021-03-30 | Pfizer Inc. | Compostos espiro heterocíclicos como inibidores de magl |
| UA127629C2 (uk) | 2018-08-13 | 2023-11-08 | Ф. Хоффманн-Ля Рош Аг | Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази |
| US20220110933A1 (en) * | 2019-01-25 | 2022-04-14 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| AU2020383502A1 (en) * | 2019-11-15 | 2022-06-30 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| CA3175210A1 (en) * | 2020-04-21 | 2021-10-28 | Cheryl A. Grice | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2023092079A1 (en) * | 2021-11-19 | 2023-05-25 | Bryant Cynthia W | Use of cannabinoid compounds to treat gastrointestinal disorders |
| KR20240128870A (ko) | 2021-12-29 | 2024-08-27 | 싸이 테라퓨틱스, 인크. | 모노아실글리세롤 리파아제(magl) 억제 |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| CN117665187B (zh) * | 2023-11-23 | 2024-08-16 | 宁波大红鹰药业股份有限公司 | 一种舒林酸中间体杂质的测定方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| CA2108575C (en) | 1991-04-16 | 2002-10-22 | Kouichi Nakamichi | Method of manufacturing solid dispersion |
| ES2149781T3 (es) | 1991-11-22 | 2000-11-16 | Procter & Gamble Pharma | Composiciones de risedronato de liberacion retardada. |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung von wachsmatrizes |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| SK7652003A3 (en) | 2000-12-18 | 2003-12-02 | Novartis Ag | Therapeutic combination of amlodipine and benazepril |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA04008073A (es) | 2002-02-20 | 2004-11-26 | Abbott Lab | Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide. |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
| EA017290B1 (ru) | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
| EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
| EA028085B1 (ru) * | 2012-01-06 | 2017-10-31 | Эбайд Терапьютикс, Инк. | Карбаматные соединения и их применение |
| MX2014011134A (es) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
| US9321750B2 (en) | 2012-04-20 | 2016-04-26 | Innov17 Llc | ROR modulators and their uses |
| BR112015009913B1 (pt) | 2012-11-02 | 2023-04-11 | Vertex Pharmaceuticals Incorporated | Comprimido compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo, seu processo de preparação, kit e método de preparação de um grânulo compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo |
| TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| JP6647592B2 (ja) | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
| EP3134092B1 (en) | 2014-04-21 | 2020-06-24 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN107660199B (zh) | 2015-03-18 | 2021-11-23 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| WO2016183097A1 (en) | 2015-05-11 | 2016-11-17 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| RS65016B1 (sr) | 2016-11-16 | 2024-01-31 | H Lundbeck As | Kristalni oblik magl inhibitora |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MX393241B (es) | 2016-11-16 | 2025-03-24 | H Lundbeck As | Formulaciones farmaceuticas. |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-11-15 RS RS20231263A patent/RS65016B1/sr unknown
- 2017-11-15 KR KR1020197017161A patent/KR102508739B1/ko active Active
- 2017-11-15 TN TNP/2019/000151A patent/TN2019000151A1/en unknown
- 2017-11-15 EP EP17872429.0A patent/EP3541807B1/en active Active
- 2017-11-15 US US16/349,142 patent/US11142517B2/en active Active
- 2017-11-15 ES ES21199077T patent/ES2966939T3/es active Active
- 2017-11-15 MA MA46866A patent/MA46866B1/fr unknown
- 2017-11-15 MA MA58133A patent/MA58133B1/fr unknown
- 2017-11-15 CN CN202210681321.7A patent/CN115093382A/zh active Pending
- 2017-11-15 CN CN201780083644.3A patent/CN110291083B/zh not_active Expired - Fee Related
- 2017-11-15 GE GEAP201715091A patent/GEP20237559B/en unknown
- 2017-11-15 SI SI201730987T patent/SI3541807T1/sl unknown
- 2017-11-15 CR CR20190242A patent/CR20190242A/es unknown
- 2017-11-15 MY MYPI2019002687A patent/MY199386A/en unknown
- 2017-11-15 SM SM20210675T patent/SMT202100675T1/it unknown
- 2017-11-15 UA UAA201905624A patent/UA124585C2/uk unknown
- 2017-11-15 PL PL21199077.5T patent/PL3964503T3/pl unknown
- 2017-11-15 HU HUE21199077A patent/HUE064559T2/hu unknown
- 2017-11-15 PL PL17872429T patent/PL3541807T3/pl unknown
- 2017-11-15 EP EP21199077.5A patent/EP3964503B1/en active Active
- 2017-11-15 SM SM20230494T patent/SMT202300494T1/it unknown
- 2017-11-15 RS RS20211501A patent/RS62665B1/sr unknown
- 2017-11-15 HR HRP20211863TT patent/HRP20211863T1/hr unknown
- 2017-11-15 AU AU2017361257A patent/AU2017361257B2/en not_active Ceased
- 2017-11-15 ES ES17872429T patent/ES2900016T3/es active Active
- 2017-11-15 HU HUE17872429A patent/HUE056973T2/hu unknown
- 2017-11-15 CA CA3043610A patent/CA3043610A1/en active Pending
- 2017-11-15 BR BR112019010003A patent/BR112019010003A2/pt not_active Application Discontinuation
- 2017-11-15 LT LTEPPCT/US2017/061875T patent/LT3541807T/lt unknown
- 2017-11-15 HR HRP20231697TT patent/HRP20231697T1/hr unknown
- 2017-11-15 JP JP2019523672A patent/JP7042548B2/ja not_active Expired - Fee Related
- 2017-11-15 JO JOP/2019/0109A patent/JOP20190109B1/ar active
- 2017-11-15 PT PT178724290T patent/PT3541807T/pt unknown
- 2017-11-15 DK DK17872429.0T patent/DK3541807T3/da active
- 2017-11-15 EA EA201991086A patent/EA201991086A1/ru unknown
- 2017-11-15 PE PE2019001013A patent/PE20191239A1/es unknown
- 2017-11-15 MX MX2019005767A patent/MX389459B/es unknown
- 2017-11-15 WO PCT/US2017/061875 patent/WO2018093953A1/en not_active Ceased
-
2019
- 2019-05-12 IL IL266548A patent/IL266548A/en unknown
- 2019-05-14 PH PH12019501068A patent/PH12019501068A1/en unknown
- 2019-05-16 DO DO2019000120A patent/DOP2019000120A/es unknown
- 2019-05-16 EC ECSENADI201935171A patent/ECSP19035171A/es unknown
- 2019-05-16 NI NI201900053A patent/NI201900053A/es unknown
- 2019-05-16 CL CL2019001340A patent/CL2019001340A1/es unknown
- 2019-05-16 CO CONC2019/0005045A patent/CO2019005045A2/es unknown
- 2019-05-16 MX MX2022000249A patent/MX2022000249A/es unknown
- 2019-05-17 ZA ZA2019/03093A patent/ZA201903093B/en unknown
-
2021
- 2021-09-08 US US17/469,535 patent/US11993588B2/en active Active
- 2021-12-13 CY CY20211101092T patent/CY1124870T1/el unknown
-
2022
- 2022-03-08 JP JP2022035398A patent/JP7350117B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903093B (en) | Crystalline forms of a magl inhibitor | |
| IL263824A (en) | Crystals in solid form in the presence of an inhibitor | |
| ZA201801417B (en) | Salts of an lsd1 inhibitor | |
| IL252756A0 (en) | solid forms of ask1 inhibitor | |
| ZA201903099B (en) | Magl inhibitors | |
| ZA201903100B (en) | Magl inhibitors | |
| IL266550A (en) | Magl inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201505658D0 (en) | Inhibitor compounds | |
| IL267393B1 (en) | Crystal forms of a Janus kinase inhibitor | |
| PL3529236T3 (pl) | Krystaliczne formy erawacykliny | |
| IL254115A0 (en) | Crystalline forms of a pyrrolpyridine compound | |
| GB201621619D0 (en) | Inhibitor compounds | |
| IL252162A0 (en) | Crystal forms of poly(adenosine diphosphate) ribose polymerase inhibitors | |
| EP3256481A4 (en) | Novel crystalline form of a proteasome inhibitor | |
| GB201522453D0 (en) | Inhibitor compounds | |
| GB201500644D0 (en) | Inhibitor compounds |